N-3 polyunsaturated fatty acids for cardiovascular risk

Area of Science:

• Cardiology
• Pharmacology
• Nutritional Science

Background:

• Omega-3 fatty acid (OM3FA) supplementation has been extensively studied for cardiovascular event risk reduction over four decades.
• Previous research largely failed to demonstrate meaningful benefits, leading to skepticism regarding their efficacy.

Purpose of the Study:

• To review and analyze recent clinical trial data on omega-3 fatty acid supplementation for cardiovascular event risk.
• To discuss the conflicting results between the REDUCE-IT and STRENGTH trials and their implications.

Main Methods:

• Comparative analysis of the REDUCE-IT and STRENGTH clinical trials, focusing on trial design and outcomes.
• Examination of the comparator agents used in each trial (mineral oil vs. corn oil).

Main Results:

• The REDUCE-IT trial reported a 25% relative risk reduction with icosapent ethyl, while the STRENGTH trial was terminated early due to futility.
• Both trials indicated an increased incidence of atrial fibrillation in the intervention groups.
• Key design differences, including the use of a mineral oil placebo in REDUCE-IT, may explain the divergent results.

Conclusions:

• The overall benefit of omega-3 fatty acid supplementation for cardiovascular events remains unclear.
• Potential harms, such as an increased risk of atrial fibrillation, must be considered.
• Current evidence suggests the risks associated with routine omega-3 fatty acid use may outweigh the potential benefits for cardiovascular event reduction.